Call to Schedule Free Consultation at Over 80 Centers Worldwide!

(844) GET-STEM

What Type of Stem Cells Are Used for Clinical Treatments?

Written by Dr. David Greene, MD, PhD, MBA on July 4, 2026

Table of Contents

Anyone researching stem cell therapy quickly runs into a confusing mix of terminology — embryonic, pluripotent, multipotent, mesenchymal, hematopoietic — often used loosely or interchangeably in marketing materials. That confusion isn’t just an academic problem. The type of stem cell used in a given treatment has direct safety implications, and some types that sound impressive on paper are not appropriate, or even legal, for clinical use anywhere in the world.

This guide breaks down the major categories of stem cells, what the research actually says about the safety of each, and which types are genuinely used in reputable regenerative medicine practice today. The goal is to help you ask better questions before pursuing any stem cell treatment — not to recommend a specific therapy for a specific condition.

Pluripotent Stem Cells: Why Embryonic and iPSCs Are Unsafe for Clinical Use

In cellular biology, stem cells are categorized by their potency—their inherent capacity to differentiate into other cell types. Pluripotent stem cells possess the ability to divide and develop into any of the three germ layers that form the human body. The most notable examples are Embryonic Stem Cells (ESCs)—derived from early-stage embryos or blastocysts—and Induced Pluripotent Stem Cells (iPSCs), which are adult cells genetically reprogrammed in a laboratory to behave like embryonic cells.

Despite their theoretical potential in lab settings, true pluripotent stem cells are not safe for direct clinical treatments anywhere in the world due to two primary medical risks. Patients seeking clarity often look into historical context, such as the ongoing stem cell research controversy, to understand how these safety and ethical debates evolved.

1. Severe Immune Rejection (MHC Class II/HLA Markers)

Embryonic stem cells retain mature human leukocyte antigens, specifically Major Histocompatibility Complex Class II (MHC-II or HLA-II) markers. The human immune system uses these surface proteins to distinguish self from non-self.

When a patient receives an embryonic or unmatched allogeneic pluripotent transplant, the host immune system immediately recognizes these markers as foreign invaders, triggering an aggressive, potentially life-threatening immune response. To understand how advanced therapies bypass this problem, it helps to examine the broader effects of stem cells on the immune system and how certain cell lines remain immune-privileged.

2. Tumor and Teratoma Formation

Because pluripotent cells can form any tissue type, their proliferation inside the human body is incredibly difficult to control once injected. In vivo, these cells frequently exhibit uncontrolled division, leading to the formation of tumors known as teratomas.

A teratoma is a complex, encapsulated tumor that can contain multiple tissue types, including hair, muscle, and bone. While often classified pathologically as benign (non-cancerous), these masses can behave aggressively. In a notable peer-reviewed case report, a patient who traveled internationally to receive unregulated embryonic stem cell injections subsequently developed progressive, persistent teratomas along the spinal cord. Despite undergoing multiple surgical resections, the tumors continued to regenerate, demonstrating the severe mechanical compression risks these masses pose to vital neural pathways. This serves as a primary reason why medical experts emphasize knowing the core stem cell basics before selecting a treatment modality.

Multipotent Stem Cells: The Safe, Clinical Gold Standard

Unlike pluripotent cells, multipotent stem cells are restricted to differentiating into a specific family of closely related cell types. This localized utility makes them highly predictable, controllable, and uniquely safe for therapeutic applications in regenerative medicine.

The two primary lineages of multipotent cells utilized safely in clinics globally are Mesenchymal Stem Cells (MSCs) and Hematopoietic Stem Cells (HSCs). These can be sourced either from the patient’s own body (autologous) or from carefully screened donor tissue (allogeneic).

Stem Cell Type

Primary Natural Sources

Primary Lineage Commitments

Common Clinical Uses

Mesenchymal (MSCs)

Umbilical Cord Tissue (Wharton’s Jelly), Adipose (Fat), Bone Marrow

Bone, Cartilage, Muscle, Fat, Connective Tissue

Orthopedics, Autoimmune Disorders, Systemic Inflammation, Tissue Repair

Hematopoietic (HSCs)

Umbilical Cord Blood, Bone Marrow, Peripheral Blood

Red Blood Cells, White Blood Cells, Platelets

Blood Disorders, Immune System Reconstitution

Mesenchymal Stem Cells (MSCs)

MSCs are the cornerstone of modern, non-surgical regenerative therapies. Beyond their ability to differentiate into structural tissue, MSCs exert powerful paracrine effects, releasing signaling molecules that reduce inflammation, stimulate local cellular healing, and modulate overactive immune responses. To understand how these cells coordinate structural repair, patients can explore how stem cell therapy works on a systemic level.

Crucially, primitive allogeneic MSCs derived from newborn umbilical cord tissue are considered “immune-privileged” or “immune-evasive.” Because they lack MHC Class II surface markers, they can be administered safely across patients without matching, presenting virtually no risk of graft rejection or tumor formation. Patients interested in these tissues can read an in-depth guide understanding umbilical cord stem cell therapy to see how they are processed and utilized.

Hematopoietic Stem Cells (HSCs)

HSCs are responsible for the constant replenishment of the body’s blood and immune systems. Clinically, they are best known for their foundational role in bone marrow transplants to treat blood cancers and bone marrow failure, though they are also found alongside MSCs in umbilical cord blood products.

Navigating Autologous vs. Allogeneic Sources

When choosing a safe type of stem cell treatment, patients must also consider the tissue source.

Autologous Sources (Self-Derived): Cells harvested from a patient’s own bone marrow or adipose (fat) tissue. While autologous therapies eliminate rejection risks, they require invasive harvesting procedures (such as a bone marrow aspirate from the pelvis or liposuction). Furthermore, the quantity and functional vitality of autologous stem cells decline significantly as a person ages or copes with systemic illness.

Allogeneic Sources (Donor-Derived): Cells derived from healthy, ethically sourced human birth tissue following scheduled, full-term Cesarean deliveries. These products provide an abundant, highly potent, and youthfully resilient supply of MSCs. They require no painful harvesting from the patient and undergo rigorous laboratory screening to ensure safety and sterility. Patients evaluating these options often weigh the clinical pros and cons of autologous and allogeneic stem cells to determine which path matches their health status.

Frequently Asked Questions

Are embryonic stem cells ever legally used to treat patients?

No. Embryonic and other truly pluripotent stem cells are not approved for direct clinical treatment anywhere in the world due to tumor formation and immune rejection risks; their use remains confined to laboratory research and highly controlled early-phase clinical trials.

What's the difference between mesenchymal and hematopoietic stem cells?

Mesenchymal stem cells differentiate into tissues like bone, cartilage, and fat, while hematopoietic stem cells differentiate into blood cell types. Both are multipotent, and both are used in established or emerging clinical applications, but for different purposes.

Is umbilical cord stem cell therapy the same as embryonic stem cell therapy?

No. Umbilical cord tissue (Wharton’s jelly) and umbilical cord blood, collected after a healthy birth, are sources of multipotent mesenchymal and hematopoietic stem cells, respectively — not pluripotent embryonic stem cells. This is a common point of public confusion.

How can I tell if a clinic is offering a safe type of stem cell therapy?

Ask specifically what cell type and source is being used (mesenchymal, hematopoietic, autologous, or allogeneic) and request documentation. Be cautious of any clinic describing its product as “pluripotent” or embryonic-derived for a standard treatment.

The Bottom Line

The stem cell field includes both well-established, multipotent cell therapies and higher-risk, pluripotent or embryonic-derived approaches that remain experimental and are not approved for standard clinical use. The distinction matters enormously for patient safety: mesenchymal and hematopoietic stem cells, properly sourced and screened, have a substantially more favorable safety record in the published literature than embryonic or pluripotent cells, which carry documented risks of immune rejection and tumor formation. Whatever provider you’re considering — R3 Stem Cell or otherwise — asking precisely what type of stem cell is being used, and requesting the evidence behind that specific application, is one of the most protective steps in choosing the right stem cell clinic for your situation.

Contact Us